Urothelial Carcinoma

Within a multicentre, open-label, phase 3 randomised control trial, investigation of the potential biomarker PD-L1 was found not to potentiate anti-tumor effects in response to atezolizumab in metasta… (full text at CIViC)

PMID 29268948 · Powles et al., 2018 · Open in CIViC

After second line treatment with cisplatin, 64 patients with positive immunohistochemical staining of CD44v9 show a significant decrease of cancer specific survival rate (p = 0.008). In multivariate a… (full text at CIViC)

PMID 29385995 · Hagiwara et al., 2018 · Open in CIViC

In retrospective analyses of two large ICI-treated solid tumor cohorts (DFCI n = 789, MSKCC n = 1250), CDKN2A loss-of-function alterations were associated with significantly worse overall survival and… (full text at CIViC)

PMID 34074656 · Adib et al., 2021 · Open in CIViC

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell line (DSH1). The variant is located in the Extracellular II domain. RT112 cells infected with lentiviral vectors cont… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell line (DSH1). The variant is located in the Extracellular II domain. In regards to the response to lapatinib, after th… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell line (VM-CUBIII). The variant is located in the signal domain. RT112 cells infected with lentiviral vectors containin… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell line (VM-CUBIII). The variant is located in the signal domain. In regards to the response to lapatinib, after three d… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell line (DSH1). The variant is located in the Extracellular I domain. RT112 cells infected with lentiviral vectors contai… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell line (DSH1). The variant is located in the Extracellular I domain. In regards to the response to lapatinib, after thr… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell line (J82). The variant is located in the transmembrane domain. RT112 cells infected with lentiviral vectors containi… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell line (J82). The variant is located in the transmembrane domain. Regarding the response to lapatinib, after three days… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell line (DSH1 and 5637). The variant is located in the Extracellular II domain. RT112 cells infected with lentiviral vec… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell lines (DSH1 and 5637). The variant is located in the Extracellular II domain. In regards to the response to lapatinib… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell line (VM-CUBI). The variant is located in the transmembrane domain. RT112 cells infected with lentiviral vectors cont… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell line (VM-CUBI). The variant is located in the transmembrane domain. Regarding the response to lapatinib, after three d… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

This study assessed the potential for mutated genes associated with urothelial bladder cancers as candidates for platinum-based neoadjuvant therapy. Nineteen patients (18 male, 3 female) diagnosed wit… (full text at CIViC)

PMID 32984035 · Hirotsu et al., 2020 · Open in CIViC

This study assessed the potential for mutated genes associated with urothelial bladder cancers as candidates for platinum-based neoadjuvant therapy. Nineteen patients (18 male, 3 female) diagnosed wit… (full text at CIViC)

PMID 32984035 · Hirotsu et al., 2020 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

Two types of UC cell lines were compared in this study. T24 and J82 which are mesenchymal subtype and overexpress FGFR1, and RT-4 and UMUC-14, epithelial subtype which do not express FGFR1. T24 and J8… (full text at CIViC)

PMID 30326563 · Kim et al., 2018 · Open in CIViC

Phase I dose-escalation cohort of patients with advanced solid tumors in which antineoplastic therapy (NCT01703481) was no longer effective using pan-FGFR inhibitor JNJ-42756493. Among 2 urothelial ca… (full text at CIViC)

PMID 31088831 · Bahleda et al., 2019 · Open in CIViC

In a pan-cancer analysis of 10,967 TCGA tumor samples across 32 cancer types, FGFR3 G370C was identified in 5 bladder urothelial carcinoma samples and was classified as an oncogenic FGFR3 mutation. G3… (full text at CIViC)

PMID 34160364 · Li et al., 2021 · Open in CIViC

In an analysis of TCGA bladder urothelial carcinoma, somatic FGFR3 G370C was recurrently identified in 3 independent tumor samples, all within the non-T-cell-inflamed subgroup. The authors described G… (full text at CIViC)

PMID 27197067 · Sweis et al., 2016 · Open in CIViC

Phase I dose-escalation cohort (NCT01703481) of patients with advanced solid tumors in which antineoplastic therapy was no longer effective using pan-FGFR inhibitor JNJ-42756493. All 16 patients with … (full text at CIViC)

PMID 31088831 · Bahleda et al., 2019 · Open in CIViC

In a Phase 3 trial (NCT03390504), patients with metastatic or surgically unresectable urothelial carcinoma, who had FGFR2 or FGFR3 alterations erdafitinib was tested against chemotherapy (docetaxel or… (full text at CIViC)

PMID 37870920 · Loriot et al., 2023 · Open in CIViC

In contrast to controls (empty vector and FGFR3 wild-type overexpression NIH-3T3 cell lines), the stable transfection of NIH-3T3 cells with FGFR3b-S249C led to ligand-independent phosphorylation of FG… (full text at CIViC)

PMID 16338952 · Bernard-Pierrot et al., 2006 · Open in CIViC

Activating FGFR3 mutations are found more frequently in lower grade / early stage urothelial carcinoma. FGFR mutations are also associated with high FGFR3 expression. FGFR3 expression therefore demons… (full text at CIViC)

PMID 16532037 · Lindgren et al., 2006 · Open in CIViC

Phase II study (NCT02465060) from NCI-MATCH Trial (EAY131) Subprotocol W addressed the use of AZD4547 (an FGFR 1-3 inhibitor) in 48 tumor patients carrying FGFR 1-3 variants. Partial responses were ob… (full text at CIViC)

PMID 32463741 · Chae et al., 2020 · Open in CIViC

Phase I dose-escalation cohort of patients with advanced solid tumors in which antineoplastic therapy (NCT01703481) was no longer effective using pan-FGFR inhibitor JNJ-42756493. Among 6 patients with… (full text at CIViC)

PMID 31088831 · Bahleda et al., 2019 · Open in CIViC

In a bridging analysis of the phase 2 BLC2001 study of patients with metastatic or locally advanced, surgically unresectable urothelial carcinoma harboring FGFR alterations, 11 patients with FGFR3 Y37… (full text at CIViC)

PMID 32304281 · Wang et al., 2020 · Open in CIViC

In a randomized controlled phase 3 trial, patients with FGFR2 or FGFR3 alterations including Y373C treated with erdafitinib vs standard chemotherapy were found to have increased overall survival (12.… (full text at CIViC)

PMID 37870920 · Loriot et al., 2023 · Open in CIViC

In this study of patients with FGFR-driven urothelial carcinoma treated with selective FGFR inhibitors, longitudinal ctDNA analysis identified emergent FGFR3 kinase domain mutations at disease progres… (full text at CIViC)

PMID 37377403 · Facchinetti et al., 2023 · Open in CIViC

This study demostrated that the progression-free survival, metastasis-free survival, and cancer-specific survival was significantly increased in patients with T393 homozygosity i.e. TT genotypes (56%,… (full text at CIViC)

PMID 15824158 · Frey et al., 2005 · Open in CIViC

4 of 16 patients with urothelial carcinoma harboring HRAS hotspot point mutations and 1 patient with an HRAS frameshift insertion had a partial response to the farnesyltransferase inhibitor tipifarnib… (full text at CIViC)

PMID 32636318 · Lee et al., 2020 · Open in CIViC

In preclinical urothelial carcinoma (UC) models, combined loss of KMT2C/KMT2D increased sensitivity to EGFR inhibitors, with Kmt2c/d-deficient cells showing significantly reduced IC50 values for afati… (full text at CIViC)

PMID 39806204 · Wang et al., 2025 · Open in CIViC

In a single-arm phase II trial of pemetrexed in previously treated metastatic urothelial carcinoma selected for MTAP deficiency by IHC (NCT02693717; n = 7), 3 patients (42%) achieved ORR, with median … (full text at CIViC)

PMID 35379845 · Alhalabi et al., 2022 · Open in CIViC

In this study of 21 patients with FGFR-driven urothelial carcinoma treated with selective FGFR inhibitors (including erdafitinib), post-progression molecular analyses (tissue and/or ctDNA sequencing) … (full text at CIViC)

PMID 37377403 · Facchinetti et al., 2023 · Open in CIViC

Patients with mutations at TERT promoter region of -124 and -146 of ATG showed poor survival in the absence but not in the presence of the variant allele of a common polymorphism with ID of rs2853669 … (full text at CIViC)

PMID 24101484 · Rachakonda et al., 2013 · Open in CIViC

This is a retrospective cohort study examining the association between tumour mutational burden (TMB) and clinical benefit from first-line single-arm immune checkpoint inhibitor (ICPI) therapy compare… (full text at CIViC)

PMID 35977348 · Graf et al., 2022 · Open in CIViC

A patient with metastatic bladder cancer that responded well to the mTOR inhibitor everolimus was shown to harbor a TSC1 frameshift truncation mutation (c.1907_1908del, p.Glu636fs) and a nonsense NF2 … (full text at CIViC)

PMID 22923433 · Iyer et al., 2012 · Open in CIViC